Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Sequential gene targeting to make chimeric tumor models with de novo chromosomal abnormalities
Author: Chambers, J.S.
Tanaka, T.
Brend, T.
Ali, H.
Geisler, N.J.
Khazin, L.
Cigudosa, J.C.
Dear, T.N.
MacLennan, K.
Rabbitts, T.H.
Citation: Cancer Research, 2014; 74(5):1588-1597
Publisher: American Association for Cancer Research
Issue Date: 2014
ISSN: 0008-5472
Statement of
Jennifer S. Chambers, Tomoyuki Tanaka, Tim Brend, Hanif Ali, Nicola J. Geisler, Leah Khazin, Juan C. Cigudosa, T. Neil Dear, Kenneth MacLennan and Terence H. Rabbitts
Abstract: The discovery of chromosomal translocations in leukemia/lymphoma and sarcomas presaged a widespread discovery in epithelial tumors. With the advent of new-generation whole-genome sequencing, many consistent chromosomal abnormalities have been described together with putative driver and passenger mutations. The multiple genetic changes required in mouse models to assess the interrelationship of abnormalities and other mutations are severe limitations. Here, we show that sequential gene targeting of embryonic stem cells can be used to yield progenitor cells to generate chimeric offspring carrying all the genetic changes needed for cell-specific cancer. Illustrating the technology, we show that MLL-ENL fusion is sufficient for lethal leukocytosis and proof of genome integrity comes from germline transmission of the sequentially targeted alleles. This accelerated technology leads to a reduction in mouse numbers (contributing significantly to the 3Rs), allows fluorescence tagging of cancer-initiating cells, and provides a flexible platform for interrogating the interaction of chromosomal abnormalities with mutations.
Keywords: Embryonic Stem Cells
Rights: © 2014 AACR.
DOI: 10.1158/0008-5472.CAN-13-1783
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.